The Dish’s Weekly Biotechnology News Wrap Up – June 3, 2016

By on June 3, 2016
Weekly Biotechnology News Wrap Up – June 03

This week’s biotechnology news headlines include, once monthly MS drug wins FDA approval, Emmanuel Charpentier’s life after CRISPR, European Commission approves GSK’s gene therapy, Novartis gets Fast Track on RSV vaccine, dollars needed for public health emergencies, Biogen and Kite Pharma CAR-T drug gets speedy review from EMA, and Jazz Pharmaceuticals agrees to buy Celator for $1.5 billion.

Cell Culture Events




BIO International Convention – June 6-9, 2016 – San Francisco, CA

Precision Medicine and Bioprocessing Conference – June 8, 2016 – Double Tree Marina Hotel, Berkeley, CA – 8:00-5:00

Selected keynote presentations by precision medicine-focused biotechnology companies developing novel therapies for heart failure and resourceful technology platforms including whole genome sequencing and CRISPR CAS addressing a broad range of diseases.

Are you looking to optimize and simplify your development of biologic therapeutics? Hands-on parallel workshop provide insight in the latest innovations designed to fine-tune your upstream and downstream development process sharing case studies, breakthroughs and novel innovative solutions that support and enhance your developing path.

Registration and attendance is complimentary – Register Here –

Cell Line Development & Engineering – June 13-15, 2016 – Parc 55 Wyndham San Francisco, CA

Co-located with

Bioconjugates: From Targets to Therapeutics

Next Generation Protein Therapeutics Summit

Annual Meeting of the International Society for Stem Cell Research – June 22-25, 2016, San Francisco, CA

Progress in Continuous Biomanufacturing – June 27-28, 2016 – Robinson College, Cambridge, UK

The conference is enhanced by the participation of several leading industrial technologists, scientific, vendors and also leading academics from Europe and USA. They have come forward to share their experience and knowledge to provide a better understanding of the current technologies and their application in continuous biomanufacturing. There is also a plenary lecture by a distinguished professor in the field of bioprocessing, and you will also benefit from access to unpublished data. This meeting will address several advancements and their successful application with data in the Technology both Upstream and downstream and also on Initiatives to process developments and project to the future direction of the industry. By joining with us you can benefit from the current state of-the-art advancements in continuous manufacturing and also learn about the successful organisations that are developing and applying these methods in-house.

Viral Safety and Raw Materials – June 2016, Vienna, Austria


“Biogen, AbbVie once-monthly MS injection wins U.S. approval,” Reuters

“The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.”

If you like this story, please see our blog titled “Albumin in Cell Culture Media – An examination of quality and function

“Emmanuelle Charpentier’s Still-Busy Life After Crispr,” The New York Times

“Emmanuelle Charpentier — one of three scientists credited with starting the gene editing revolution — willingly turned her life over to science. For 25 years, she was a scientific nomad, working at nine institutions in five countries, scrambling for research funds, paid so little she barely scraped by. Now, at 47, with her gene editing discovery, her life has changed.”

If you like this story, please see our blog titled “The CRISPR/Cas9 System and its Applications”

“EC approves GSK’s Strimvelis,” BioCentury

“GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said the European Commission approved gene therapy Strimvelis (GSK2696273) to treat patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) for whom no suitable HLA-matched related stem cell donor is available. GSK said the approval is the first granted to a corrective gene therapy for children.”

If you like this story, please see our blog titled “Gene Therapy Strengthened by Recent Successes”

“Novavax gains FDA fast track as it ramps up late-stage RSV vaccine studies,” Washington Business Journal

“Novavax Inc. has won a potentially lucrative fast-track designation from the U.S. Food and Drug Administration for one of its lead vaccine candidates to protect older patients against a respiratory virus known as RSV.”

If you like this story, please see our blog titled “Poster: Purpose-designed Protein A resins for Improved Downstream Process and Cost Efficiency in MAb purification

“Hustling Dollars for Public Health,” The New York Times

“On Tuesday, a woman infected with the Zika virus gave birth to a girl with microcephaly, a malformed head, in New Jersey. Federal officials say there are more than 300 pregnant women possibly infected with Zika around the country. Yet every time an emergency like this happens, public health officials must go begging bowl in hand to Congress for the funds to deal with it. And as the current squabble between Republicans and President Obama over money for the Zika virus shows, there’s no guarantee of significant or even timely relief.”

If you like this story, please see our blog titled “Cool Tool – Off the Shelf Optimized CHO Media and Feed

“Biogen, Kite Pharma gain EMA hurry-up reviews,” Fierce Biotech

“Biogen’s ($BIIB) Alzheimer’s candidate aducanumab and Kite’s ($KITE) much-hyped experimental CAR-T blood cancer drug KTE-C19 are some of the first drugs to gain a speedy review under a new system from the European Medicines Agency.”

If you like this story, please see our blog titled “New Poster: Proving Clonality – A Documented Clonality Report for Regulatory Submission

“Jazz Pharmaceuticals Agrees to Buy Celator for $1.5 Billion,” Bloomberg

“Jazz Pharmaceuticals Plc agreed to buy Celator Pharmaceuticals Inc. for about $1.5 billion to gain an experimental medicine for a rare blood cancer.”

If you like this story, please see our blog titled “Cell Culture and Single Cell Passaging of Human Pluripotent Stem Cells Without the Need for ROCK Inhibitor

Leave a Reply

Your email address will not be published. Required fields are marked *